Last reviewed · How we verify
ARV-471 in combination with palbociclib (IBRANCE®) (arv-471-in-combination-with-palbociclib-ibrance)
ARV-471 binds to estrogen receptors in breast cancer cells, while palbociclib inhibits CDK4/6, together blocking tumor growth.
At a glance
| Generic name | arv-471-in-combination-with-palbociclib-ibrance |
|---|---|
| Sponsor | Pfizer Inc. |
| Phase | Phase 1 |
Mechanism of action
ARV-471 targets estrogen receptors, which are often overactive in breast cancer, reducing tumor cell proliferation. Palbociclib stops cancer cells from dividing by inhibiting CDK4/6 enzymes, enhancing the anti-tumor effect.
Approved indications
Common side effects
Key clinical trials
- A Phase 1/2 Trial of ARV-471 Alone and in Combination With Palbociclib (IBRANCE®) in Patients With ER+/HER2- Locally Advanced or Metastatic Breast Cancer (PHASE1, PHASE2)
- Study of PF-07248144 in Advanced or Metastatic Solid Tumors (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: